Viridian Therapeutics, Inc.\DE (VRDN) Enterprise Value (2016 - 2025)
Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Enterprise Value data on record, last reported at -$868.2 million in Q4 2025.
- For Q4 2025, Enterprise Value fell 20.99% year-over-year to -$868.2 million; the TTM value through Dec 2025 reached -$868.2 million, down 20.99%, while the annual FY2025 figure was -$868.2 million, 20.99% down from the prior year.
- Enterprise Value reached -$868.2 million in Q4 2025 per VRDN's latest filing, down from -$490.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$109.3 million in Q2 2021 and bottomed at -$868.2 million in Q4 2025.
- Average Enterprise Value over 5 years is -$427.1 million, with a median of -$427.9 million recorded in 2022.
- Peak YoY movement for Enterprise Value: plummeted 610.83% in 2021, then surged 34.83% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$197.0 million in 2021, then plummeted by 115.55% to -$424.6 million in 2022, then fell by 12.44% to -$477.4 million in 2023, then crashed by 50.32% to -$717.6 million in 2024, then fell by 20.99% to -$868.2 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$868.2 million in Q4 2025, -$490.9 million in Q3 2025, and -$563.4 million in Q2 2025.